Genetics Primer for Breast Surgeons

Wednesday, May 1, 2019

7:00 AM-5:00 PM

COURSE MODERATORS: Kevin Hughes, MD and Molly Sebastian, MD

FACULTY: David Euhus, MD; Kevin Hughes, MD; Cary Kaufman, MD; Scott Kurtzman, MD; Jennifer Plichta, MD; Barry Rosen, MD; Molly Sebastian, MD; Julia Shaner, MS, CGC; Linda Smith, MD; Pat Whitworth, MD

COURSE DESCRIPTION:

Breast surgeons are well-positioned to become leaders in the area of cancer genetics. To prepare breast surgeons for this new role, this course will provide an update on selecting the appropriate genetic test panel; identifying candidates for initial testing or update testing; and interpreting pathogenic, normal, and variant results. This course will also focus on pretest and post-test counseling and management; cascade testing of family members; patient selection; and interpretation and management of somatic (tumor) genetic testing.

COURSE OBJECTIVES:

At the conclusion of this course, participants should be able to:

- Describe common pathogenic mutations among breast cancer patients and their family members as well as the unaffected public (the scope of the problem)
- Review the latest NCCN guidelines on who should be offered genetic testing (who should be tested and informed consent)
- Provide details of the most common pathogenic mutations, moderate risk mutations and lower risk
 mutations and appropriate risk management options (positive test results and what they mean for the
 patient's cancer risk)
- Understand the differences among labs offering genetic testing

CME Information

The American Society of Breast Surgeons designates this live activity for a maximum of 7.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Genetics Primer for Breast Surgeons

Wednesday, May 1, 2019

PRELIMINARY AGENDA

7:00 am-7:30 am	Check-in and Breakfast	
7:30 am-7:35 am	Welcome and Introduction	Molly Sebastian, MD
7:35 am-8:05 am	The Problem, the Genes, and the Patients Genetic Testing: Defining the Problem and Defining the Surgeon's Role in Addressing the Problem	Kevin Hughes, MD
8:05 am-9:00 am	Genes and Pathways: Update on Pathogenic Variants and Their Cancer Risk	David Euhus, MD
9:00 am-9:30 am	Identification of Patients Who Need Genetic Testing	Jennifer Plichta, MD
9:30 AM-9:45 AM	Panel Discussion	Faculty
9:45 AM-10:15 AM	Break	
10:15 AM-10:45 AM	Counseling and Test Interpretation Cancer Genetic Testing: Extended Pretest Counseling, Abbreviated Pretest Counseling	Linda Smith, MD
10:45 AM-11:15 AM	Can Pretest Counseling Be Eliminated?	Jennifer Plichta, MD
11:15 AM-11:45 AM	Cancer Genetic Test Interpretation, Post-Test Counseling	Molly Sebastian, MD
11:45 АМ-12:00 РМ	Panel Discussion	Faculty
12:00 PM-1:00 PM	Lunch	
1:00 рм-1:30 рм	Management Overview and Beyond the Basics Management of Pathogenic Variants, a Negative Test and Variants of Uncertain Significance	Pat Whitworth, MD
1:30 PM-2:00 PM	Interpretation of Genetic Tests Other than Clinical Cancer Panels and the Counseling and Management Required	Kevin Hughes, MD
2:00 PM-2:30 PM	Beyond the Initial Report: Cascade Genetic Testing and Managing Variant Reclassification	Julia Shaner, MS, CGC
2:30 pm-3:00 pm	Break	
3:00 рм-3:30 рм	Implementation and the Future How to Implement Testing in Your Practice (Insurance Coverage, Documentation, etc.)	Barry Rosen, MD
3:30 рм-4:00 рм	The Standards: What They Are, How They Got There, and What They May Become	Scott Kurtzman, MD
4:00 pm-4:30 pm	What Can We Expect in the Future? How to Stay Current?	Cary Kaufman, MD
4:30 pm-5:00 pm	Panel Discussion	Faculty